{"nctId":"NCT01656161","briefTitle":"Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer","startDateStruct":{"date":"2012-07"},"conditions":["Prostate Cancer"],"count":120,"armGroups":[{"label":"Triptorelin embonate 22.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Triptorelin embonate 22.5 mg"]}],"interventions":[{"name":"Triptorelin embonate 22.5 mg","otherNames":["Pamorelin"]}],"eligibilityModule":{"eligibilityCriteria":"Summary Inclusion Criteria:\n\n* Meets protocol-specified criteria for qualification and contraception\n* Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related food, drink and medications\n* Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures\n\nSummary Exclusion Criteria:\n\n* Has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters\n* Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff; 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3) the analysis of results","healthyVolunteers":false,"sex":"MALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving and Maintaining Castrate Levels of Serum Testosterone (<1.735 Nmol/L)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.61","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Showing ≤ 1.0 IU/L Increase in Serum Luteinising Hormone (LH) From 0 Hour to 2 Hours Post-injection on Day 1 and Day 169","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.83","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Prostate Specific Antigen (PSA) Through Day 337","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-83.20","spread":"38.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-83.48","spread":"38.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-85.43","spread":"33.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-82.89","spread":"40.74"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Presented a Real \"Acute-on-chronic\" (AOC) Phenomenon (Testosterone Levels ≥ 1.735 Nmol/L 48 Hours After the Second Injection While Previously Castrated)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Testosterone Pharmacodynamic (PD) Metrics for First Injection: Area Under the Concentration vs Time Curve (AUC)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"224.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Testosterone PD Metrics for First Injection: Maximum Concentration (Cmax)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Testosterone PD Metrics for First Injection: Time to Peak Serum/Plasma Concentration (Tmax)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":"40.02"}]}]}]},{"type":"SECONDARY","title":"Testosterone PD Metrics for First Injection: Time to Castration (Tcast)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Triptorelin PK Metrics for Both Injections: Area Under the Concentration vs Time Curve (AUC)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.44","spread":null}]}]}]},{"type":"SECONDARY","title":"Triptorelin PK Metrics for Both Injections: Cmax","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Triptorelin PK Metrics for Both Injections: Concentration 0 Hour","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":120},"commonTop":["Hot flush","Hypertension","Urinary tract infection","Constipation","Lethargy"]}}}